Mesothelioma, Malignant Clinical Trial
Official title:
Diagnostic and Prognostic Role of 11C-Methionine PET/CT Imaging in Patients Affected by Malignant Pleural Mesothelioma (MPM) and Candidate to Pleurodesis
Prospective exploratory study specifically investigating the role of 11C-Methionine PET/CT imaging in patients affected by Malignant Pleural Mesothelioma (MPM) and candidate to pleurodesis.
This is a single-center, open-label study, lasting 36 months including an estimated period of
24 months for the enrollment and max 12 months of follow-up. All patients affected by MPM and
referred to our Institution eligible for therapeutic pleurodesis and subsequent platinum- and
pemetrexed-based chemotherapy will be enrolled. In all cases patients will be investigated
with 11C-Methionine PET/CT and 18F-FDG PET/CT before talc pleurodesis, one week after and at
the end of three cycles of chemotherapy.
A minimum number of 20 patients will be considered for the analysis.
;
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Recruiting |
NCT06057935 -
A Study of Additional Chemotherapy After Surgery for People With Malignant Peritoneal Mesothelioma
|
Phase 2 | |
| Recruiting |
NCT04104776 -
A Study of CPI-0209 in Patients With Advanced Solid Tumors and Lymphomas
|
Phase 1/Phase 2 | |
| Recruiting |
NCT05429866 -
Immunological Variables Associated to ICI Toxicity in Cancer Patients
|
Phase 2 | |
| Recruiting |
NCT04981119 -
Solid Tumor Analysis for HLA Loss of Heterozygosity (LOH) and Apheresis for CAR T- Cell Manufacturing
|
||
| Terminated |
NCT02357147 -
Study of the Safety and Efficacy of Amatuximab in Combination With Pemetrexed and Cisplatin in Subjects With Unresectable Malignant Pleural Mesothelioma (MPM)
|
Phase 2 | |
| Recruiting |
NCT06281860 -
Treatment Pleural Carcinosis of Pressurized IntraThoracic Hyperthermic Aerosol Cisplatin Administration
|
Phase 1 | |
| Completed |
NCT02303899 -
Combination of Gemcitabine and Imatinib Mesylate in Pemetrexed-pretreated Patients With Pleural Mesothelioma
|
Phase 2 | |
| Recruiting |
NCT05380713 -
......SMARTEST Trial......
|
Phase 2 | |
| Recruiting |
NCT06299163 -
NM32-2668 in Adult Patients With Selected Advanced Solid Tumors
|
Phase 1 | |
| Recruiting |
NCT05568680 -
SynKIR-110 for Mesothelin Expressing Ovarian Cancer, Cholangiocarcinoma or Mesothelioma
|
Phase 1 | |
| Terminated |
NCT03502746 -
Phase II Nivolumab and Ramucirumab for Patients With Previously-Treated Mesothelioma
|
Phase 2 | |
| Active, not recruiting |
NCT05451849 -
A Phase 1/2 Trial of TC-510 In Patients With Advanced Mesothelin-Expressing Cancer
|
Phase 1/Phase 2 | |
| Recruiting |
NCT06251310 -
SW-682 in Advanced Solid Tumors
|
Phase 1 | |
| Recruiting |
NCT05944237 -
HTL0039732 in Participants With Advanced Solid Tumours
|
Phase 1/Phase 2 | |
| Active, not recruiting |
NCT05455424 -
Niraparib Efficacy in Patient With Unresectable Mesothelioma
|
Phase 2 | |
| Recruiting |
NCT05324436 -
A Study of Yervoy and Opdivo Combination Therapy in Participants With Unresectable Advanced/Recurrent Malignant Pleural Mesothelioma (MPM)
|
||
| Active, not recruiting |
NCT03654833 -
Mesothelioma Stratified Therapy (MiST) : A Multi-drug Phase II Trial in Malignant Mesothelioma
|
Phase 2 | |
| Recruiting |
NCT05136677 -
A Study to Evaluate Nivolumab in Combination With Ipilimumab Versus Pemetrexed With Cisplatin or Carboplatin for Unresectable Pleural Mesothelioma in Chinese Participants
|
Phase 2 | |
| Not yet recruiting |
NCT05698238 -
Clinical Study to Evaluate Safety and Dosing of CA9hu-1 in Patients With Advanced Solid Tumours
|
Phase 1 | |
| Not yet recruiting |
NCT05188859 -
First Line Sintilimab Combined With Anlotinib and Platinum Doublet Chemotherapy in Malignant Pleural Mesothelioma
|
Phase 2 |